tiprankstipranks
Trending News
More News >
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Statistics & Valuation Metrics

Compare
467 Followers

Total Valuation

Kezar Life Sciences has a market cap or net worth of $32.15M. The enterprise value is $5.38M.
Market Cap$32.15M
Enterprise Value$5.38M

Share Statistics

Kezar Life Sciences has 7,305,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,305,800
Owned by Insiders25.63%
Owned by Institutions46.67%

Financial Efficiency

Kezar Life Sciences’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -68.07%.
Return on Equity (ROE)-0.72
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-68.07%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee0.00
Profits Per Employee-1.52M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Kezar Life Sciences is -5.85. Kezar Life Sciences’s PEG ratio is <0.01.
PE Ratio-5.85
PS Ratio0.00
PB Ratio0.31
Price to Fair Value4.19
Price to FCF-0.47
Price to Operating Cash Flow-0.47
PEG Ratio<0.01

Income Statement

In the last 12 months, Kezar Life Sciences had revenue of 0.00 and earned -83.74M in profits. Earnings per share was -1.15.
Revenue0.00
Gross Profit0.00
Operating Income-90.61M
Pretax Income-83.74M
Net Income-83.74M
EBITDA-81.10M
Earnings Per Share (EPS)-1.15

Cash Flow

In the last 12 months, operating cash flow was -68.54M and capital expenditures -37.00K, giving a free cash flow of -68.58M billion.
Operating Cash Flow-68.54M
Free Cash Flow-68.58M
Free Cash Flow per Share-9.39

Dividends & Yields

Kezar Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.48
52-Week Price Change-38.80%
50-Day Moving Average4.28
200-Day Moving Average6.06
Relative Strength Index (RSI)55.94
Average Volume (3m)31.89K

Important Dates

Kezar Life Sciences upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date

Financial Position

Kezar Life Sciences as a current ratio of 6.76, with Debt / Equity ratio of 9.93%
Current Ratio6.76
Quick Ratio6.76
Debt to Market Cap0.02
Net Debt to EBITDA0.32
Interest Coverage Ratio-56.88

Taxes

In the past 12 months, Kezar Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Kezar Life Sciences EV to EBITDA ratio is -5.73, with an EV/FCF ratio of -6.25.
EV to Sales0.00
EV to EBITDA-5.73
EV to Free Cash Flow-6.25
EV to Operating Cash Flow-6.26

Balance Sheet

Kezar Life Sciences has $114.36M in cash and marketable securities with $10.24M in debt, giving a net cash position of -$104.13M billion.
Cash & Marketable Securities$114.36M
Total Debt$10.24M
Net Cash-$104.13M
Net Cash Per Share-$14.25
Tangible Book Value Per Share$1.60

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Kezar Life Sciences is $12.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.50
Price Target Upside184.09% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast18.17%

Scores

Smart Score5
AI Score42
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis